| Authors: |
Brunner SF; Quotient Therapeutics, Inc., Cambridge, MA, USA; Flagship Pioneering, Inc., Cambridge, MA, USA., Martincorena I; Quotient Therapeutics, Inc., Cambridge, MA, USA; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK., Mannino G; Children's Research Institute, Departments of Pediatrics and Internal Medicine, Simmons Comprehensive Cancer Center, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA., Fox CS; Quotient Therapeutics, Inc., Cambridge, MA, USA., Stratton MR; Quotient Therapeutics, Inc., Cambridge, MA, USA; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK., Rubens JR; Quotient Therapeutics, Inc., Cambridge, MA, USA; Flagship Pioneering, Inc., Cambridge, MA, USA., Campbell PJ; Quotient Therapeutics, Inc., Cambridge, MA, USA; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK., Zhu H; Quotient Therapeutics, Inc., Cambridge, MA, USA; Children's Research Institute, Departments of Pediatrics and Internal Medicine, Simmons Comprehensive Cancer Center, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: hao.zhu@utsouthwestern.edu. |
